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Background
In 2001, Cuba launched a national ARV access program
to provide ARV therapy free of cost. The first-line ther-
apy combinations are composed of two nucleoside
reverse transcriptase (RT) inhibitors (NRTIs) (AZT
+3TC or d4T+3TC) associated with a non-nucleoside
RT inhibitor (NNRTI) (NVP or EFV) or a protease inhi-
bitor (PI) (IDV).
Purpose of the study
To identify resistance mutations in HIV-1 isolated
obtained from Cuban treated patients presenting clinical
and/or immunological failure.
Methods
Plasma samples from 84 HIV-1 infected patients were
collected from June to November 2009 at the Tropical
Medicine Institute from Havana City. Viral RNA frag-
ments corresponding to the PR and RT region were
amplified, sequenced and sub typed. Drug resistance
was interpreted according to http://hivdb.stanford.edu.
Results
The most frequently found subtypes and recombinants
were: B (40.4%), D (32.1%, presumably CRF19_cpx), C
(9.5%) and CRF18_cpx (8.3%). The PI mutations,
I54VML, M46IL and L90MVL were found in 61.7, 57.4
and 53.1% of cases, respectively. Whereas for RTI, pri-
mary mutations at positions M184V, T215Y, D67N,
Y181C and K103N were present in 98.6, 67.1, 43.8, 47.5
and 40.9% of subjects, respectively. A high level
resistance to antiretroviral drug was observed
(NRTI=86.9%, NNRTI=72.6% and PI=55.9%). Full class
resistance (NRTI/NRTI/PI) was found in 22 patients
(26.1%), who presented history of several changes of
treatment (media of 1.35 treatment changes per year,
from 4 to 13 year under treatment).
Conclusions
The present study reveals a high rate of resistance com-
pared with other international reports suggesting that
alternative strategies for initial therapy and lab monitor-
ing should be considered. These findings also warrant
the study of antiviral resistance in therapy-naïve
patients.
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